The TRAVERSE trial, published in the New England Journal of Medicine in 2023, followed 5,246 men with hypogonadism and preexisting cardiovascular risk for an average of 33 months
Our team in Burlington verifies your coverage, determines eligibility, and manages all prior authorization requirements
This makes it especially appealing for individuals who are returning to health practices after a long break or juggling multiple personal and professional responsibilities
Obesity is a chronic relapsing disease
Many users find that their second and third cycles produce further improvement, likely because each cycle builds upon the structural gains of the previous one
Compared to the risks of untreated obesity, the potential side effects of GLP-1 weight loss medications are usually minimal and manageable